Komori
Other Disclosures4592SanBio Company LimitedPharmaceuticals

Notice of administration in the second post-marketing case of “Akuugo® Injection for Intracerebral Implantation”

On 27 October 2026, the cell therapy product “Akuugo® Injection for Intracerebral Implantation” was administered to the second post-marketing patient at Okayama University Hospital. The patient’s progress following administration will continue to be monitored carefully by the hospital.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
2
Post-marketing administrations (cumulative)
Wording
Conditional
How definitive the wording is.

Announced details

Akugo® Intracerebral Implant Injection (generic name: vandefitemcel)
Applicable field (uses covered by this announcement)

Chronic motor paralysis associated with traumatic brain injury

Launch date27 October 2026 (actual: administered at Okayama University Hospital)
What the company reported numerically
Usage history

Second post-marketing administration. The first post-marketing administration was carried out at Hokkaido University Hospital on 2 October 2026, and the second at Okayama University Hospital on 27 October 2026.

Relationship between the counterparty and the company
SanBio Company Limited4592
Relationship with the Company

Okayama University Hospital is the medical institution and administration site where SanBio’s regenerative medicine product was administered. Capital and personnel relationships are not disclosed.

CounterpartyOkayama University Hospital

The location, representative, capital, year of establishment and other details are not disclosed. It is stated to be a university hospital.

Award/certification name

Product covered by the Sakigake Designation System, RMAT designation, and Advanced Therapy Medicinal Product (ATMP) designation

Awarding / certifying body

Ministry of Health, Labour and Welfare; U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA)

Registration number and expiry date

Conditional and time-limited marketing approval was obtained on 31 July 2024. The approval number and expiry date are not disclosed.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

James SL et al., Global Burden of Disease Study 2016(Lancet Neurol 2019);Selassie AW et al.(J Head Trauma Rehabil 2008);Zaloshnja E et al.(J Head Trauma Rehabil 2008)

Announced details
ItemDetails
Names of Products / Services CoveredAkugo® Intracerebral Implant Injection (generic name: vandefitemcel)
CounterpartyOkayama University Hospital
Counterparty overviewThe location, representative, capital, year of establishment and other details are not disclosed. It is stated to be a university hospital.
Relationship with the CompanyOkayama University Hospital is the medical institution and administration site where SanBio’s regenerative medicine product was administered. Capital and personnel relationships are not disclosed.
Launch date27 October 2026 (actual: administered at Okayama University Hospital)
Applicable areaChronic motor paralysis associated with traumatic brain injury
Award/certification nameProduct covered by the Sakigake Designation System, RMAT designation, and Advanced Therapy Medicinal Product (ATMP) designation
Awarding / certifying bodyMinistry of Health, Labour and Welfare; U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA)
Registration number and expiry dateConditional and time-limited marketing approval was obtained on 31 July 2024. The approval number and expiry date are not disclosed.
Usage historySecond post-marketing administration. The first post-marketing administration was carried out at Hokkaido University Hospital on 2 October 2026, and the second at Okayama University Hospital on 27 October 2026.
SourceJames SL et al., Global Burden of Disease Study 2016(Lancet Neurol 2019);Selassie AW et al.(J Head Trauma Rehabil 2008);Zaloshnja E et al.(J Head Trauma Rehabil 2008)
Items this document does not state (7)
Contract ValueOffering priceContract DateLocationLocation scaleQuantitative EffectsImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The administration was carried out after the prescribed procedures had been completed. The company explained that the patient’s postoperative course would continue to be monitored carefully at Okayama University Hospital.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of administration in the second post-marketing case of “Akuugo® Injection for Intracerebral Implantation” | SanBio Company Limited (4592) timely disclosure | Komori